Periodical
Association between urate-lowering therapy and kidney failure in patients with chronic kidney disease
| العنوان: | Association between urate-lowering therapy and kidney failure in patients with chronic kidney disease |
|---|---|
| المؤلفون: | Mouheb, Agathe, Lambert, Oriane, Alencar de Pinho, Natalia, Jacquelinet, Christian, Laville, Maurice, Combe, Christian, Fouque, Denis, Frimat, Luc, Massy, Ziad A., Laville, Solène M., Liabeuf, Sophie |
| المصدر: | Journal of Nephrology; 20250101, Issue: Preprints p1-11, 11p |
| مستخلص: | Background: Hyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is subject to debate. The objective of the present study was to describe the prevalence of inappropriate urate-lowering therapy prescriptions and evaluate the association between urate-lowering therapy prescription and the progression of kidney disease in patients with CKD. Methods: CKD-REIN is a French, nationwide, prospective cohort of 3,033 nephrology outpatients with CKD (eGFR < 60 mL/min/1.73 m2). Prescriptions of urate-lowering therapy drugs (allopurinol or febuxostat) were recorded prospectively. The appropriateness of each prescription was evaluated according to the patient’s kidney function at baseline and during follow-up. Propensity score-matched, cause-specific Cox proportional hazards regression models were used to assess the association between incident urate-lowering therapy use and CKD progression (defined as the initiation of kidney replacement therapy (KRT) but also in other ways). Results: At baseline, 987 of the 3009 patients included in this study (median age: 69; men: 66%) were receiving urate-lowering therapy; 396 of these 987 patients were receiving an inappropriate prescription with regard to their kidney function. During a 5-year follow-up period, 70% of the 396 urate-lowering therapy prescriptions remained inappropriate. In the propensity score-matched cohort (n= 674), 136 patients started KRT. Compared with non- urate-lowering therapy use, urate-lowering therapy use was not significantly associated with a slowing in CKD progression, regardless of the definition used (HR |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 11218428 17246059 |
|---|---|
| DOI: | 10.1007/s40620-024-02179-0 |